{
    "clinical_study": {
        "@rank": "35321", 
        "arm_group": [
            {
                "arm_group_label": "12 hourly capsule fasted", 
                "arm_group_type": "Active Comparator", 
                "description": "4 mg 12 hourly capsule - strong pain killer fasted"
            }, 
            {
                "arm_group_label": "12 hourly capsule fed", 
                "arm_group_type": "Active Comparator", 
                "description": "4 mg 12 hourly capsule - strong pain killer fed"
            }, 
            {
                "arm_group_label": "12 hourly capsule with antagonist fasted", 
                "arm_group_type": "Experimental", 
                "description": "4 mg 12 hourly capsule strong painkiller with antagonist fasted"
            }, 
            {
                "arm_group_label": "12 hourly capsule with antagonist fed", 
                "arm_group_type": "Experimental", 
                "description": "4 mg 12 hourly capsule strong painkiller with antagonist fed"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess whether an opioid antagonist has any impact on the release of a strong painkiller\n      in the blood when it is given to healthy volunteers when they have eaten and also when they\n      have fasted."
        }, 
        "brief_title": "A Study to Assess How the Body Processes a Strong Painkiller When it is Given Alongside a Drug That Counteracts the Side Effects of Strong Painkillers in a Fasted and Fed State.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "This is an exploratory study to assess the influence of an opioid antagonist on the\n      pharmacokinetics of a strong painkiller when co-administered in a fasted and fed state.\n\n      Determination is by measurement of drug concentrations in the blood at serial collection\n      time points pre-dose until 32 hours post-dose, following an administration of a single oral\n      dose. Pharmacokinetics parameters of AUC and Cmax are the primary endpoints."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Healthy male or female subjects aged 18 to 55 inclusive Healthy and free of significant\n        abnormal findings as determined by medical history, physical examination, vital signs,\n        laboratory tests and ECG."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133820", 
            "org_study_id": "HMX1507", 
            "secondary_id": "2013-005522-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "12 hourly capsule fed", 
                "intervention_name": "4 mg 12 hourly capsule - strong pain killer fasted", 
                "intervention_type": "Drug", 
                "other_name": "MR2XXX"
            }, 
            {
                "arm_group_label": "12 hourly capsule fasted", 
                "intervention_name": "4 mg 12 hourly capsule - strong pain killer fed", 
                "intervention_type": "Drug", 
                "other_name": "MR2XXX"
            }, 
            {
                "arm_group_label": "12 hourly capsule with antagonist fed", 
                "intervention_name": "12 hourly capsule strong painkiller with antagonist fasted)", 
                "intervention_type": "Drug", 
                "other_name": "MR2XXX"
            }, 
            {
                "arm_group_label": "12 hourly capsule with antagonist fasted", 
                "intervention_name": "4 mg 12 hourly capsule strong painkiller with antagonist fed", 
                "intervention_type": "Drug", 
                "other_name": "MR2XXX"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Narcotic Antagonists"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy Volunteer", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "last_name": "Dr Collier"
            }, 
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "state": "Nottinghamshire", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Quotient Clinical Limited"
            }, 
            "investigator": {
                "last_name": "Dr Collier, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A 4-part, Single-dose, Open-label, Randomised, Crossover, Exploratory Study in Healthy Subjects to Assess the Influence of an Opioid Antagonist on How the Body Processes a Strong Painkiller, When Co-administered in a Fasted and Fed State.", 
        "overall_contact": {
            "email": "info@contact-clinical-trial.com", 
            "last_name": "Margaret C Wilson"
        }, 
        "overall_contact_backup": {
            "email": "info@contact-clinical-trial.com", 
            "last_name": "Jill Kiteley"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics parameters AUC and Cmax", 
            "safety_issue": "No", 
            "time_frame": "Up to 32 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133820"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AEs will be recorded through spontaneous reporting", 
                "measure": "Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "7 to 10 days"
            }, 
            {
                "description": "Vital signs - blood pressure, pulse rate, tympanic temperature and respiration rate", 
                "measure": "Vital Signs", 
                "safety_issue": "No", 
                "time_frame": "0 to  32 hours"
            }, 
            {
                "description": "Clinical laboratory tests - blood samples will be taken at screening and post-study medical for routine laboratory analysis (haematology, blood chemistry and urinalysis", 
                "measure": "Clinical Laboratory Tests", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 7-10"
            }, 
            {
                "description": "ECGs", 
                "measure": "ECG", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, 1 our post-dose and Day 7-10"
            }
        ], 
        "source": "Mundipharma Research Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma Research Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}